

Errata for Nutrition Management of Patients with Inherited Metabolic Disorders

Phyllis B. Acosta

Corrections highlighted in yellow and red below.

Page 27

Table 2-1 Expected Analyte Profiles for MS/MS Newborn Screening Disorders

MS/MS ANALYTES	POSSIBLE DISORDER(S)	ACRONYM	McKUSICK NUMBER
↑Cit	Citrullinemia (argininosuccinate synthetase deficiency) Argininosuccinic aciduria (argininosuccinate lyase deficiency) Citron Deficiency	ASA CIT CIT II	215700 207900 603471
↑Met	Homocystinuria (cystathionine β synthetase deficiency) Methionine adenosyltransferase deficiency	HCY MET	236200 250850
↑Phe, Phe/Tyr	Phenylketonuria (phenylalanine hydroxylase deficiency) Biotpterin synthesis defects Biotpterin reg	PKU BIOPT-BS	261600 261630
↑Tyr	Tyrosinemia: Fumarylacetoacetic acid hydrolase deficiency Methylacetoacetic acid isomerase deficiency Tyrosine aminotransferase deficiency p-OH phenylpyruvatic acid dioxygenase deficiency	TYR Ia * TYR Ib * TYR II TYR III	276700 603758 276600 276710
↑Leu (± Val)	Maple syrup urine disease (branched chain α-keto acid dehydrogenase deficiency)	MSUD	248600
↓ C0	Primary carnitine deficiency (carnitine plasma membrane transporter deficiency/ carnitine uptake deficiency)	CUD	212140
↑C3, C3/C2	Methylmalonic acidemia (methylmalonyl CoA mutase deficiency and cobalamin defects) Cobalamin A Cobalamin B Cobalamin C Cobalamin D Propionic acidemia (propionyl CoA carboxylase deficiency)	MUT CblA CblB CblC CblD PROP	251000 251100 251110 277410 277400 606054
↑C4	Short chain acyl CoA dehydrogenase deficiency Isobutyryl CoA dehydrogenase deficiency	SCAD IBG	201470 611283
↑C5	Isovaleric acidemia (isovaleryl CoA dehydrogenase deficiency) 2-methyl butyryl CoA dehydrogenase deficiency/ short branched chain CoA dehydrogenase deficiency	IVA 2MBG (SBCAD)**	243500 600006 (600301)
↑C5:1 (±C5OH)	β ketothiolase deficiency (acetoacetyl CoA thiolase deficiency)	BKT	248600
↑C5-DC	Glutaric acidemia type I (glutaryl CoA dehydrogenase deficiency)	GA I	231670
↑C5-OH (± C5:1)	3-methylcrotonyl glycinuria (3 methyl crotonyl CoA carboxylase deficiency)	3MCC	210200
↑C5-OH (± C6-DC)	3-OH-3-methyl-glutaryl-CoA lyase deficiency	HMG	246450
↑C5-OH (± C3)	Multiple carboxylase deficiency	MCD	253260
↑C5-OH	3-methylglutaconyl hydratase deficiency	3MGA	250950
↑C8 and C8/C10 (±C6,C10:1)	Medium chain acyl CoA dehydrogenase deficiency	MCAD	201450
↑C14:1 and ↑C14:1/C12:1 (± C14, C16, C18:1)	Very long chain acyl CoA dehydrogenase deficiency	VLCAD	201475
↑C16, C18:1	Carnitine palmitoyl transferase II deficiency Carnitine-acylcarnitine translocase deficiency	CPTII CACT	255110 212138
↑C16-OH, C18:1-OH	Long chain hydroxy acyl CoA dehydrogenase deficiency Trifunctional protein deficiency	LCHAD TFP	609016 609015
↑C4, C5, C5-DC, C6, C8, C12, C14, C16	Glutaric acidemia type II (multiple acyl CoA dehydrogenase deficiency)	GA II	231680

* TYR Ia and Ib may be missed by MS/MS NBS targeting elevated Tyr – see text

**2MBG and SBCAD are two names for the same disorder

Figure 2.5 The Carnitine Transport Cycle (correct diagram below)




Table 3-1. Recommended Daily Intakes [RDIs] for Patients Ingesting Elemental Diets

Nutrient	Recommended Intake at Age*						
	0 <6 mos	6 < 12 mos	1 < 4 yr	4 < 7 yr	7 < 11 yr	11 < 19 yr	Adult
Protein†, g	4.5 - 3.0 / 100 kcal	≥ 35	≥ 40	≥ 50	≥ 65	≥ 70	1st trim 70 2nd trim 85 3rd trim 100
Fat, g	6.0 - 3.3 / 100 kcal	> 30	45	55	60	60-70	75

Errata for Nutrition Management of Patients with Inherited Metabolic Disorders

Phyllis B. Acosta

Linoleic acid,	4.4	4.6	7.0	10.0	12.0	16.0	17.0	14.0
g								
□-linolenic	0.5	0.5	0.7	0.9	1.2	1.6	1.6	1.5
acid, g								
Energy [†] , kcal	120/kg	110/kg	900-1800	1300-2300	1650-3300	1500-1900	2000-3300	1700-2700
Fluid, mL	1.5/kcal	1.5-1.0/kcal	900-1800	1300-2300	1650-3300	1500-1900	2000-3300	1700-2700
Minerals								
Calcium, mg	400	600	800	800	1300	1300	1200	1300
Chloride								
mg	55-150/100 kcal		1500	1900	2300	2300	2300	2300
mEq	1.55-4.2/100 kcal		42.3	54	65	65	65	65
Chromium, µg	0.2	5.5	11	15	25	35	30	3.0
Copper, mg	0.60	0.80	1.5	2.0	2.5	3.0	3.0	3.5
Iodine, µg	25-75 / 100 kcal		90	90	120	150	150	220
Iron ^{§,¶} , mg	10	15	15	15	15	18	18	48
Magnesium, mg	50	75	150	200	250	420	420	430
Manganese, mg	0.3	0.6	1.5	2.0	2.0	2.5	2.5	3.0
Molybdenum, µg	2.0	3.0	17	22	34	45	45	50
Phosphorus, mg	350	500	800	800	1250	1250	1000	1250
Potassium,								
mg	80-200/100 kcal		117	149	176	184	184	184
mEq	2.0-5.1/100 kcal		3.0	3.8	4.5	4.7	4.7	4.7
Selenium, µg	20	25	30	40	50	65	65	70
Sodium								
mg	20-60/100 kcal		1000	1200	1500	1500	1500	1500
mEq	0.87-2.61/100 kcal		43	52	65	65	65	65
Zinc, mg	5	5	10	10	15	15	15	20
Vitamins								
A								
IU	250-750 / 100 kcal		400	500	700	900	900	1000
µg RAE	75 - 225 / 100 kcal		120	150	210	270	270	300
D								
IU	40-100/100 kcal		400	400	400	400	400	480
µg	1.0-2.5/100 kcal		10	10	10	10	10	12

Phyllis B. Acosta

Page 120

Metabolic pathway of Tyrosine and Phenylalanine:

- Guanosine triphosphate (GTP)** → **Dihydroneopterin triphosphate** (Enzyme: *GPT cyclohydrolase*)
- Dihydroneopterin triphosphate** → **6-pyruvoyl-tetrahydrobiopterin** (Enzyme: *6-pyruvoyl-tetrahydrobiopterin synthase*)
- 6-pyruvoyl-tetrahydrobiopterin** → **H₄ biopterin** (Enzyme: *Sepiapterin reductase*, uses **NADPH**, produces **NADP⁺**)
- H₄ biopterin** → **H₂ biopterin** (Enzyme: *Dihydropyridine reductase*, uses **NAD⁺**, produces **NADH + H⁺**)
- Dietary protein** → **Phenylalanine** (Chemical structure: N[C@@H](Cc1ccccc1)C(=O)O)
- Phenylalanine** ↔ **Tissue protein**
- Phenylalanine** → **Tyrosine** (Enzyme: *Phenylalanine hydroxylase*, uses **O₂**, produces **H₂O**)
- Tyrosine** (Chemical structure: N[C@@H](Cc1ccc(O)cc1)C(=O)O) ↔ **Tissue protein**
- Tyrosine** → **p-Hydroxyphenylpyruvic acid** (Enzyme: *Tyrosine Aminotransferase*)
- p-Hydroxyphenylpyruvic acid** (Chemical structure: OC(=O)C(=O)Cc1ccc(O)cc1) → **Homogentisic acid** (Enzyme: *p-Hydroxyphenylpyruvic acid Dioxygenase*)
- Homogentisic acid** (Chemical structure: OC(=O)C(=O)Cc1ccc(O)cc1) → **Maleylacetoacetic acid** (Chemical structure: OC(=O)C(=O)C=C(C(=O)O)C(=O)O)
- Maleylacetoacetic acid** ↔ **Fumarylacetoacetic acid** (Chemical structure: OC(=O)C(=O)C=C(C(=O)O)C(=O)O)
- Fumarylacetoacetic acid** → **Succinylacetoacetate** (Chemical structure: OC(=O)C(=O)C=C(C(=O)O)C(=O)O)
- Succinylacetoacetate** → **Succinylacetone** (Chemical structure: CC(=O)CC(=O)C(=O)O)
- Succinylacetone** → **Fumaric acid** (Chemical structure: OC(=O)C=CC(=O)O)
- Fumaric acid** + **Acetoacetic acid** (Chemical structure: CC(=O)CC(=O)O) → **Tyrosine** (Enzyme: *Tyrosine Aminotransferase*)
- Phenylalanine** → **Phenylpyruvic Acid** (Chemical structure: OC(=O)C(=O)Cc1ccccc1)
- Phenylpyruvic Acid** → **Phenylacetate** (Chemical structure: CC(=O)Cc1ccccc1)
- Phenylacetate** → **Phenylacetylglutamine** (Chemical structure: NC(=O)CC(=O)Cc1ccccc1)
- Phenylalanine** → **Phenylethylamine** (Chemical structure: NCCc1ccccc1)
- Phenylethylamine** → **Phenylacetate** (Enzyme: *Phenylethylamine oxidase*)
- Phenylalanine** → **Orthohydroxyphenylacetate** (Chemical structure: OC(=O)Cc1ccc(O)cc1)
- Orthohydroxyphenylacetate** → **Phenylpyruvic Acid** (Enzyme: *Orthohydroxyphenylacetate decarboxylase*)
- Phenylpyruvic Acid** → **Phenyllactate** (Chemical structure: OC(=O)Cc1ccccc1)
- Phenyllactate** → **Phenylacetate** (Enzyme: *Phenyllactate decarboxylase*)
- Phenylacetate** → **Phenylacetylglutamine** (Enzyme: *Phenylacetylglutamine synthetase*)

Page 125


After 10 years of age, plasma PHE concentrations could be increased to > 600 umol/L and at 20 years to > 1200 umol/L.

Page 175

The disorders for which nutrition management are outlined in this chapter are MSUD, isovaleric acidemia (IVA), β -methylcrotonyl-CoA carboxylase deficiency (β MCC), β -hydroxy- β -methylglutaryl-CoA (HMG-CoA) lyase deficiency, and mitochondrial acetoacetyl-CoA thiolase deficiency, commonly known as β -ketothiolase (β KT) deficiency.

Page 177

Figure 6.1 Metabolism of Branched-Chain Amino Acids (correct diagram below)



Errata for Nutrition Management of Patients with Inherited Metabolic Disorders

Phyllis B. Acosta

Page 201

Table 6-6 Nutrition Composition and Sources of LEU-Free Medical Foods (continued)

Medical Foods	Modified ^a Nutrient(s) (mg/100 g)	Protein Equiv ^b (g/100 g, source)	Fat (g/100 g, source)	Carbohydrate (g/100 g, source)	Energy (kcal/100 g/kJ/100 g)	Linoleic Acid/ α -Linolenic Acid (mg/100 g)
Nutricia ^f						
XLeu Analog TM	Glycine 2050 L-carnitine 10 Taurine 20	13 Amino acids ^c	20.9 High oleic safflower, coconut, and soy oils	59 Com syrup solids, galactose	475/1985	3025/NA
XLeu Maxamaid [®]	Glycine 3990 L-carnitine 20 Taurine 140	25 Amino acids ^c	<0.1	56 Sugar, com syrup solids	324/1754	0
XLeu Maxamum [®]	Glycine 6300 L-carnitine 39 Taurine 140	40 Amino acids ^c	<1	34 Sugar, com syrup solids	305/1275	0

Notes:

NA = not available.

Values listed, although accurate at time of publication, are subject to change. For current information, refer to product labels.

^aLEU-free.

^bNitrogen, g \times 6.25 = g protein.

^cAbbott Nutrition, 3300 Stelzer Road, Columbus, Ohio, 43219. 800-551-5838.

^dAll except glycine are in the L-form.

^eMead Johnson Nutritionals, 2400 West Lloyd Expressway, Evansville, Indiana 47721. 800-457-3550.

^fNutricia North America, PO Box 117, Gaithersburg, Maryland 20884. 800-365-7354.


Page 205

Increased concentrations of 3-hydroxyisovaleric acid and β - methylcrotonylglycine are found in urine with the absence of methylcitrate, and α -methyl- β -hydroxybutyrate ~~is~~ found in combined carboxylase deficiency.¹²⁸

Page 238

CYS is used as an abbreviation for both cystine and cysteine since interconversion in the body is nonenzymatic.

Figure 7.1



Page 242

Use of ratios, such as MET to leucine (LEU) and isoleucine (MET:LEU + ILE), can also help reduce false detection of hypermethioninemia.

Page 246

More recently, Picker and Levy suggested the following protocol:

Page 248

However, using current diagnostic criteria, review of these studies did not verify this diagnosis.⁶⁷

In addition, long-term biochemical control is necessary to maintain ocular health in patients with CβS deficiency.

Errata for Nutrition Management of Patients with Inherited Metabolic Disorders

Phyllis B. Acosta

Page 249

Another recent study suggested that abnormal HCY metabolites replace dehydroascorbic acid in connective tissue metabolism.⁸⁷

Page 260

The edema resolved when therapy was discontinued.¹³³

Page 261

Table 7.4 *Diet Plan for a Neonate Who Weighs 3.5 kg Diagnosed with Vitamin B₆ Nonresponsive Homocystinuria*

<i>Food</i>	<i>Amount</i>	<i>MET (mg)</i>	<i>CYS (mg)</i>	<i>Protein (g)</i>	<i>Energy (kcal)</i>
Similac® Advance® infant formula with iron, powder	26 g	71	42	2.8	137
Hominex®-1 powder	63 g	0	284	9.5	302
Cystine solution (13 mg/100 mL) ^a	600 mL	0	78	0.0	0
Water to make ^b					615
Total		71	404	12.3	615 439
Per kg body weight		20	115	3.5	125

^aL-CYS has a solubility of ~13 mg/100 g water at room temperature. *Source: Ajinomoto. Amino Acid Handbook.* Ajinomoto, Japan. 2004.

^bAdd water to yield a total 615 mL (~21 fl oz @ 20 kcal/ fl oz).

Page 268

However, severe MATI/III deficiency can cause demyelination with reduced cognitive function later in childhood.^{165,168}

Page 270

Errata *for* Nutrition Management of Patients with Inherited Metabolic Disorders

Phyllis B. Acosta

Methionine Synthase (CblG) Deficiency (OMIM 250940)¹³ and Methionine Synthase
Reductase (CblE) Deficiency (OMIM 236270)¹³

Figure 8.1 Metabolic Pathways for Isoleucine, Valine, Threonine, Methionine, and Odd-Chain Fatty Acids (correct diagram below)





Table 8.3 Formulation, Nutrient Composition, and Sources of Medical Foods for Patients with Propionic Acidemia or Methyilmalonic Acidemia (per 100 g powder), Continued

Medical Foods	Modified Nutrient(s) (mg/100 g)	Protein Equiv ^a (g/100 g, source)	Fat (g/100 g, source)	Carbohydrate (g/100 g, source)	Energy (kcal/100 g/kJ/100 g)	Linoleic Acid/ α-Linolenic Acid (mg/100 g)
Nutricia North America						
XMTVI Analog [®]	MET 0, VAL 0 ILE trace, THR 0 L-carnitine 10 Taurine 20	13.0 Amino acids ^c	20.9 High oleic safflower, coconut, soy oils	59.0 Corn syrup solids, galactose	475/1985	3025/ND
XMTVI Maxamaid [®]	MET 0, VAL 0 ILE trace, THR 0 L-carnitine 20 Taurine 140	25.0 Amino acids ^c	<0.1	56.0 Sugar, corn syrup solids	324/1354	0/0
XMTVI Maxamum [®]	MET 0, VAL 0 ILE trace, THR 0 L-carnitine 39 Taurine 140	40.0 Amino acids ^c	<1.0	34.0 Sugar, corn syrup solids	305/1275	0/0
Milupa OS2 [®]	MET 0, VAL 0 ILE 0, THR 0 L-carnitine 0 Taurine 0	56.0 Amino acids ^c	0.0	18.9 Sugar	300/1254	0/0

Page 309

Figure 8.5 Metabolism of Lysine and Tryptophan (correct diagram below)



Page 320

Kolker et al.¹⁵³ recommended energy intakes at approximately 120% DRIs.

Page 322

Deficient trace mineral and vitamin intakes and plasma concentrations have been reported in children consuming elemental formulas.^{56,180}

Page 323

Researchers have reported nearnormal development in many patients treated neonatally.^{158,163,173}

Page 350

Proprietary infant formulas made with soy protein isolate contain fat and essential fatty acids (see Appendix F).

Page 394

Examples of an emergency letter can be found on the FAOD parent support website at <http://www.fodsupport.org>.

Page 396

For VLCAD, a sum of the long-chain C14:0, C14:1, C16:0, C16:1, C18:0, C18:1, and C18:2 plasma acylcarnitine esters can be calculated.

Page 407

Figure 11.1 Inherited Metabolic Disorders in the Urea Cycle and Nutrition Approaches to Their Management (correct diagram below)

